KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Accounts Payables (2016 - 2025)

Astrazeneca has reported Accounts Payables over the past 11 years, most recently at $25.3 billion for Q4 2025.

  • Quarterly results put Accounts Payables at $25.3 billion for Q4 2025, up 12.53% from a year ago — trailing twelve months through Dec 2025 was $25.3 billion (up 12.53% YoY), and the annual figure for FY2025 was $25.3 billion, up 12.53%.
  • Accounts Payables for Q4 2025 was $25.3 billion at Astrazeneca, up from $22.5 billion in the prior quarter.
  • Over the last five years, Accounts Payables for AZN hit a ceiling of $25.3 billion in Q4 2025 and a floor of $2.6 billion in Q4 2022.
  • Median Accounts Payables over the past 5 years was $22.4 billion (2023), compared with a mean of $18.3 billion.
  • Biggest five-year swings in Accounts Payables: crashed 86.54% in 2022 and later soared 777.41% in 2023.
  • Astrazeneca's Accounts Payables stood at $18.9 billion in 2021, then plummeted by 86.54% to $2.6 billion in 2022, then soared by 777.41% to $22.4 billion in 2023, then increased by 0.41% to $22.5 billion in 2024, then grew by 12.53% to $25.3 billion in 2025.
  • The last three reported values for Accounts Payables were $25.3 billion (Q4 2025), $22.5 billion (Q4 2024), and $22.4 billion (Q4 2023) per Business Quant data.